690 related articles for article (PubMed ID: 21459216)
21. Intravitreal triamcinolone acetonide for diabetic diffuse macular edema: preliminary results of a prospective controlled trial.
Massin P; Audren F; Haouchine B; Erginay A; Bergmann JF; Benosman R; Caulin C; Gaudric A
Ophthalmology; 2004 Feb; 111(2):218-24; discussion 224-5. PubMed ID: 15019365
[TBL] [Abstract][Full Text] [Related]
22. Intravitreal triamcinolone acetonide for diffuse diabetic macular edema: phase 2 trial comparing 4 mg vs 2 mg.
Audren F; Lecleire-Collet A; Erginay A; Haouchine B; Benosman R; Bergmann JF; Gaudric A; Massin P
Am J Ophthalmol; 2006 Nov; 142(5):794-99. PubMed ID: 16978576
[TBL] [Abstract][Full Text] [Related]
23. Introduction.
Puliafito CA
Ophthalmic Surg Lasers Imaging Retina; 2016 Apr; 47(4 Suppl):S4. PubMed ID: 27096288
[No Abstract] [Full Text] [Related]
24. Fluocinolone acetonide for the treatment of diabetic macular edema.
Haritoglou C; Mayer W; Wolf A
Expert Rev Clin Pharmacol; 2016; 9(3):367-74. PubMed ID: 26681198
[TBL] [Abstract][Full Text] [Related]
25. Fluocinolone acetonide implantable device for diabetic retinopathy.
Schwartz SG; Flynn HW
Curr Pharm Biotechnol; 2011 Mar; 12(3):347-51. PubMed ID: 20939799
[TBL] [Abstract][Full Text] [Related]
26. Treating Diabetic Macular Oedema (DMO): real world UK clinical outcomes for the 0.19mg Fluocinolone Acetonide intravitreal implant (Iluvien™) at 2 years.
Fusi-Rubiano W; Mukherjee C; Lane M; Tsaloumas MD; Glover N; Kidess A; Denniston AK; Palmer HE; Manna A; Morjaria R
BMC Ophthalmol; 2018 Feb; 18(1):62. PubMed ID: 29486754
[TBL] [Abstract][Full Text] [Related]
27. Intravitreal triamcinolone as an adjunct to standard laser therapy in coexisting high-risk proliferative diabetic retinopathy and clinically significant macular edema.
Mirshahi A; Shenazandi H; Lashay A; Faghihi H; Alimahmoudi A; Dianat S
Retina; 2010 Feb; 30(2):254-9. PubMed ID: 20057344
[TBL] [Abstract][Full Text] [Related]
28. Iluvien Implantation for Uveitis and Uveitic Macular Edema.
Reddy AK; Burkholder BM; Khan IR; Thorne JE
Ocul Immunol Inflamm; 2018; 26(2):315-316. PubMed ID: 27736275
[No Abstract] [Full Text] [Related]
29. Long-term Effects of Intravitreal 0.19 mg Fluocinolone Acetonide Implant on Progression and Regression of Diabetic Retinopathy.
Wykoff CC; Chakravarthy U; Campochiaro PA; Bailey C; Green K; Cunha-Vaz J
Ophthalmology; 2017 Apr; 124(4):440-449. PubMed ID: 28081945
[TBL] [Abstract][Full Text] [Related]
30. Intravitreal triamcinolone as a primary therapy in diabetic macular oedema.
Karacorlu M; Ozdemir H; Karacorlu S; Alacali N; Mudun B; Burumcek E
Eye (Lond); 2005 Apr; 19(4):382-6. PubMed ID: 15309024
[TBL] [Abstract][Full Text] [Related]
31. Intravitreal triamcinolone plus sequential grid laser versus triamcinolone or laser alone for treating diabetic macular edema: six-month outcomes.
Lam DS; Chan CK; Mohamed S; Lai TY; Lee VY; Liu DT; Li KK; Li PS; Shanmugam MP
Ophthalmology; 2007 Dec; 114(12):2162-7. PubMed ID: 17459479
[TBL] [Abstract][Full Text] [Related]
32. The transient efficacy of a single intravitreal triamcinolone acetonide injection for diabetic macular edema.
Desatnik H; Habot-Wilner Z; Alhalel A; Moroz I; Glovinsky J; Moisseiev J
Isr Med Assoc J; 2006 Jun; 8(6):383-7. PubMed ID: 16833165
[TBL] [Abstract][Full Text] [Related]
33. Duration of the effect of intravitreal triamcinolone acetonide as treatment for diffuse diabetic macular edema.
Jonas JB; Degenring RF; Kamppeter BA; Kreissig I; Akkoyun I
Am J Ophthalmol; 2004 Jul; 138(1):158-60. PubMed ID: 15234306
[TBL] [Abstract][Full Text] [Related]
34. Triple therapy of vitrectomy, intravitreal triamcinolone, and macular laser photocoagulation for intractable diabetic macular edema.
Kang SW; Park SC; Cho HY; Kang JH
Am J Ophthalmol; 2007 Dec; 144(6):878-885. PubMed ID: 17936715
[TBL] [Abstract][Full Text] [Related]
35. [Fluocinolone acetonide (ILUVIEN®) micro-implant for chronic diabetic macular edema].
Soubrane G; Behar-Cohen F
J Fr Ophtalmol; 2015 Feb; 38(2):159-67. PubMed ID: 25601517
[TBL] [Abstract][Full Text] [Related]
36. Repeated intravitreal high-dosage injections of triamcinolone acetonide for diffuse diabetic macular edema.
Jonas JB; Spandau UH; Kamppeter BA; Vossmerbaeumer U; Harder B; Sauder G
Ophthalmology; 2006 May; 113(5):800-4. PubMed ID: 16530840
[TBL] [Abstract][Full Text] [Related]
37. Discontinuous to continuous therapy for persistent diabetic macular edema leads to reduction in treatment frequency.
Adams OE; Schechet SA; Hariprasad SM
Eur J Ophthalmol; 2021 Mar; 31(2):612-619. PubMed ID: 31964171
[TBL] [Abstract][Full Text] [Related]
38. ISIS-DME: a prospective, randomized, dose-escalation intravitreal steroid injection study for refractory diabetic macular edema.
Kim JE; Pollack JS; Miller DG; Mittra RA; Spaide RF;
Retina; 2008 May; 28(5):735-40. PubMed ID: 18463518
[TBL] [Abstract][Full Text] [Related]
39. Intravitreal triamcinolone for diabetic macular edema: comparison of 1, 2, and 4 mg.
Hauser D; Bukelman A; Pokroy R; Katz H; Len A; Thein R; Parness-Yossifon R; Pollack A
Retina; 2008 Jun; 28(6):825-30. PubMed ID: 18536598
[TBL] [Abstract][Full Text] [Related]
40. Intravitreal triamcinolone acetonide for macular oedema owing to retinal vein occlusion.
Patel PJ; Zaheer I; Karia N
Eye (Lond); 2008 Jan; 22(1):60-4. PubMed ID: 16902493
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
